Provectus Biopharmaceuticals Inc.

10/09/2025 | Press release | Distributed by Public on 10/09/2025 06:08

Provectus Biopharmaceuticals Positions PV-10 as a Differentiated Alternative to Traditional Vaccine Adjuvants; University of Calgary Research Highlights Novel STING-Pathway[...]

Provectus Biopharmaceuticals Inc. published this content on October 09, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 09, 2025 at 12:08 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]